Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2615 - Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): longer follow-up efficacy and safety data


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site



Taofeek Owonikoko


Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289


T.K. Owonikoko1, K.P. Papadopoulos2, M. Gil-Martin3, V. Moreno4, A.K. Salama5, E. Calvo6, H. Safran7, A. González-Martín8, R. Aljumaily9, D. Mahadevan10, J. Niu11, K. Kal Mohan12, J. Li13, E. Stankevich14, M. Mathias12, I. Lowy12, M.G. Fury12, H.M. Babiker15

Author affiliations

  • 1 Department Of Hematology And Medical Oncology, Winship Cancer Institute, Emory University, 30322 - Atlanta/US
  • 2 Clinical research, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
  • 3 L’hospitalet De Llobregat, Institut Català d’Oncologia, 08908 - Barcelona/ES
  • 4 Clinical research Phase 1 Trials Unit, START Madrid-FJD, Hospital Fundación Jiménez Díaz, 28040 - Madrid/ES
  • 5 Division Of Medical Oncology, Duke University, Durham/US
  • 6 Clinical research, START Madrid, Centro Integral Oncológico Clara Campal, 28050 - Madrid/ES
  • 7 Department Of Medicine, Brown University, Providence/US
  • 8 Clinica Universidad De Navarra, Formerly of MD Anderson International España, Madrid/ES
  • 9 Department Of Hematology/oncology, Oklahoma University Medical Center, Oklahoma City/US
  • 10 Department Of Medicine, The University of Arizona Cancer Center, Tucson, AZ, USA. Formerly of The University of Tennessee Health Science Center and West Cancer Center, Memphis/US
  • 11 Department Of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert/US
  • 12 Clinical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown/US
  • 13 Biostatistics & Data Management, Regeneron Pharmaceuticals, Inc., Basking Ridge/US
  • 14 Clinical Sciences, Regeneron Pharmaceuticals, Inc., 07920 - Basking Ridge/US
  • 15 Department Of Medicine, University of Arizona Cancer Center, 85724-5024 - Tucson/US

Abstract 2615


Cemiplimab (REGN2810) demonstrated a positive risk/benefit profile and produced antitumour activity in patients (pts) with advanced CSCC in the primary analysis, by independent central review, of a phase 1 CSCC expansion cohorts (ECs). We now report longer follow-up data from the CSCC ECs of the phase 1 study (NCT02383212).


Pts with distantly metastatic or unresectable locally/regionally advanced CSCC were enrolled in ECs 7 and 8, respectively. All pts received cemiplimab 3 mg/kg every 2 weeks over 30 minutes by intravenous infusion for up to 48 weeks. Tumour measurements were performed by RECIST 1.1 every 8 weeks to determine overall response rate (ORR; complete response [CR] + partial response [PR]) according to intention to treat. The data cut-off date was 20 Jan, 2018. Tumour response in this report was by investigator assessment.


A total of 26 pts were enrolled (21 M/ 5 F; 10 in EC 7, 16 in EC 8; median age: 72.5 years [range: 55–88]; ECOG performance status was 1 in 16 pts and 0 in 10 pts). Median duration of follow-up was 11.9 months (range: 1.1–18.2). Median duration of cemiplimab exposure was 36.0 weeks. The most common treatment-emergent adverse event (TEAE) of any grade was fatigue (26.9%). The only TEAEs of grade ≥3 that occurred in more than one pt were hypercalcaemia and skin infection (each 7.7%). ORR was 50.0% (95% CI: 29.9–70.1), with 2 CRs and 11 PRs; 5 patients had stable disease (SD), 6 had progressive disease, and 2 were not evaluable for response. Durable disease control rate (SD or response for ≥105 days) was 57.7% (95% CI: 36.9–76.6). Median time to response was 1.9 months (range: 1.7–7.5). The median duration of response has not been reached, and as of the data cut-off date, for pts with CR or PR, the observed duration of response exceeded 6 months in 9 pts and 12 months in 5 pts.


The increasing duration of response in this analysis provides further evidence of a positive risk/benefit profile for cemiplimab in pts with advanced CSCC.

Clinical trial identification


Legal entity responsible for the study

Regeneron Pharmaceutical, Inc. and Sanofi.


The study was sponsored by Regeneron Pharmaceutical, Inc. and Sanofi.

Editorial Acknowledgement

Medical writing support under the direction of the authors was provided by Emmanuel Ogunnowo, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc. and Sanofi according to Good Publication Practice guidelines (http://annals.org/aim/fullarticle/2424869/good-publication-practice-communicating-company-sponsored-medical-research-gpp3).


T.K. Owonikoko: Fees for consulting or advisory: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune. A.K. Salama: Fees for consulting or advisory, Speakers’ bureau: Bristol-Myers. E. Calvo: Research funding: Boehringer Ingelheim, Roche/Genentech, BMS, Novartis, PsiOxus, Nanobiotix, Janssen, Abbvie, PharmaMar, PUMA, Sanofi, Lilly, Pfizer, Merck, Nektar, Amcure, Amgen, AstraZeneca, Principia, Bayer, CytomX, H3, Incyte, Kura, LOXO, Macrogenics, Menarini, Merck, Serono, Merus, Millenium, Rigontec, Tahio, TesaroReceipt; Honoraria, Consultation fees: Novartis, Nanobiotix, Janssen-Cilag, PsiOxus Therapeutics, Seattle Genetics, Pierre Fabre, Boehringer Ingelheim, Cerulean Pharma, EUSA, Abbvie, Celgene; Speaker’s bureau fees: Novartis. A. González-Martín: Consulting, advisory, speakers’ bureau, Travel accommodation expenses: AstraZeneca, Tesaro, Roche, Pharmamar. D. Mahadevan: Speakers’ bureau, Travel, accommodation expenses: Abbvie. J. Niu: Consulting, Advisory role: Genentech, Biodesix, Paradigm, Ignyta, AstraZeneca, Teueda. K. Kal Mohan: Employee, Shareholder: Regeneron Pharmaceuticals, Inc. J. Li: Jingjin Employee, Shareholder: Regeneron Pharmaceuticals, Inc., Novartis. E. Stankevich: Employee: Regeneron Pharmaceuticals, Inc.; Shareholder: Regeneron Pharmaceuticals, Inc., Celgene, Bristol-Myers Squibb, Merck. M. Mathias: Employee, Shareholder: Regeneron Pharmaceuticals, Inc. I. Lowy: Employee, Shareholder, Fees Travel and accommodation expenses, Leadership: Regeneron Pharmaceuticals, Inc. M.G. Fury: Employee, Shareholder, Patents, Royalties, Other intellectual property: Regeneron Pharmaceuticals, Inc. H.M. Babiker: Honoraria: Bayer, Sirtex; Consulting, Advisory role fees: Celgene, Endocyte. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.